COLUMBIA, Md., Aug. 6, 2025 /PRNewswire/ -- Advarra, the market leader in regulatory reviews and a leading provider of clinical research technology, today announced a major expansion of its Study ...
New integrations with industry leaders in EDC, eConsent, IRT/RTSM, eCOA, payments, and patient engagement expands Advarra's connected ecosystem, giving sponsors, CROs, and research sites secure, ...
Entered into Clinical Study Collaboration and Supply Agreement with Gilead to evaluate IDE397, IDEAYA's MAT2A inhibitor, in combination with sacituzumab-govitecan-hziy ("Trodelvy") Gilead's Trop-2 ...
Site burden has always been a trending topic in clinical research. What is the impact on study startup? One major issue is that protocol design fails to consider site workflows. When trials are ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results